Edwards Lifesciences Corporation (NYSE:EW) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 196.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 105,358 shares of the medical research company's stock after acquiring an additional 69,825 shares during the quarter. Teacher Retirement System of Texas' holdings in Edwards Lifesciences were worth $7,636,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $49,038,000. Dynamic Advisor Solutions LLC increased its holdings in Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the period. Simplify Asset Management Inc. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $5,979,000. Finally, Assetmark Inc. lifted its holdings in shares of Edwards Lifesciences by 786.9% in the 4th quarter. Assetmark Inc. now owns 1,082 shares of the medical research company's stock worth $80,000 after buying an additional 960 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.7%

Edwards Lifesciences stock traded up $0.53 during midday trading on Monday, reaching $77.32. The company's stock had a trading volume of 591,633 shares, compared to its average volume of 4,483,954. Edwards Lifesciences Corporation has a 52-week low of $58.93 and a 52-week high of $95.25. The stock has a market capitalization of $45.35 billion, a P/E ratio of 11.04, a PEG ratio of 3.86 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The stock's 50-day simple moving average is $76.12 and its 200-day simple moving average is $73.27.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period last year, the business earned $0.66 EPS. Edwards Lifesciences's revenue for the quarter was up 6.2% on a year-over-year basis. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the transaction, the chief executive officer directly owned 58,284 shares in the company, valued at $4,366,054.44. This represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,648 shares of company stock valued at $2,998,866. Company insiders own 0.34% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on EW. Truist Financial cut their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Finally, Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Hold" and an average target price of $80.20.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.